- Home
- SJT vs GBIO Comparison
SJT vs GBIO Comparison
Compare SJT & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- GBIO
- Stock Information
- Founded
- SJT 1980
- GBIO 2016
- Country
- SJT United States
- GBIO United States
- Employees
- SJT N/A
- GBIO N/A
- Industry
- SJT Oil & Gas Production
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SJT Energy
- GBIO Health Care
- Exchange
- SJT Nasdaq
- GBIO Nasdaq
- Market Cap
- SJT 180.8M
- GBIO 165.5M
- IPO Year
- SJT N/A
- GBIO 2020
- Fundamental
- Price
- SJT $4.03
- GBIO $1.32
- Analyst Decision
- SJT
- GBIO Strong Buy
- Analyst Count
- SJT 0
- GBIO 2
- Target Price
- SJT N/A
- GBIO $7.50
- AVG Volume (30 Days)
- SJT 178.6K
- GBIO 161.6K
- Earning Date
- SJT 11-29-2024
- GBIO 11-06-2024
- Dividend Yield
- SJT 8.60%
- GBIO N/A
- EPS Growth
- SJT N/A
- GBIO N/A
- EPS
- SJT 0.19
- GBIO N/A
- Revenue
- SJT $11,031,594.00
- GBIO $18,582,000.00
- Revenue This Year
- SJT N/A
- GBIO $188.06
- Revenue Next Year
- SJT N/A
- GBIO N/A
- P/E Ratio
- SJT $20.31
- GBIO N/A
- Revenue Growth
- SJT N/A
- GBIO 514.08
- 52 Week Low
- SJT $3.21
- GBIO $1.10
- 52 Week High
- SJT $7.22
- GBIO $4.65
- Technical
- Relative Strength Index (RSI)
- SJT 54.55
- GBIO 23.42
- Support Level
- SJT $3.71
- GBIO $2.14
- Resistance Level
- SJT $4.02
- GBIO $2.57
- Average True Range (ATR)
- SJT 0.17
- GBIO 0.21
- MACD
- SJT -0.01
- GBIO -0.09
- Stochastic Oscillator
- SJT 86.49
- GBIO 6.02
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.